Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019).
Company facts
| Company | Amgen Inc. |
|---|---|
| Symbol | AMGN |
| Exchange | XNAS |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market cap | $206.78B (Massive market data, 2026-09-10) |
| Employees | 31,500 |
| Country | United States |
| Website | https://www.amgen.com |
Trading — Amgen Inc.
| Last price | $377.35 |
|---|---|
| Change | -1.34% |
| Previous close | $382.47 |
| Day range | $377.22 – $386.99 |
| 50-day average | $398.37 |
| 200-day average | $358.94 |
| Average volume | 2,709,513 |
Price basis: 2026-09-11T20:59:27.833906+00:00
Valuation and financial health
| Earnings per share | $16.17 |
|---|---|
| Price / book | 17.69 |
| Price / cash flow | 16.57 |
| Enterprise value / EBITDA | 15.54 |
| Enterprise value / sales | 6.56 |
| Debt / equity | 4.90 |
| Current ratio | 1.37 |
| Dividend yield | 2.56% |
| Free cash flow | $10.18B |
| Cash ratio | 0.55 |
| Enterprise value | $250.09B |
Reported 2026-09-10
Earnings
| Report date | 2026-11-03 |
|---|---|
| Session | After Hours |
| Fiscal quarter ending | Sep/2026 |
| EPS estimate | $5.69 |
| Year-ago EPS | $5.64 |
| Analyst estimates | 9 |
Source: Nasdaq.com public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for AMGN are on the IntelTrends dashboard.